Review evaluates efficacy and safety of DMTs in multiple sclerosis, highlighting impacts on relapse rates.
This review examines the role of disease-modifying therapies (DMTs) in treating multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. DMTs have been shown to reduce relapse rates, slow disease progression, and improve quality of life for patients with MS. The different classes of DMTs, including injectable, oral, and infusion therapies, offer varying benefits and risks. Understanding the efficacy, safety, and impact of DMTs on quality of life is essential for healthcare providers to deliver optimal care and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Okun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: